Moderna Gets $590 Million of Federal Funding For Influenza Vaccines
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines
Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.
Moderna Announces Updates on Pandemic Influenza Program
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
Moderna stock surges on bird flu vaccine funding
Shares of Moderna (NASDAQ:MRNA) jumped 5% following reports that it had been awarded $590 million for the development of a bird flu vaccine. The funding, provided by the Department of Health and Human Services,
As bird flu concerns grow, scientists race to develop new vaccines
As fears grow of a possible bird flu pandemic in humans, the federal government is pouring more money into the development of new vaccines, including an mRNA shot.
U.S. Gives Moderna $590 Million to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
Is Moderna a Bad-News Buy for 2025?
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...